Navigation Links
Florida researchers receive JDRF 'Excellence in Clinical Research Award'
Date:6/16/2008

Washington, DC, June 13, 2008 Mary Tyler Moore, the Juvenile Diabetes Research Foundation's international chairman, and her husband, S. Robert Levine, M.D., presented the sixth annual "Excellence in Clinical Research Award" to a team of Florida scientists at JDRF's annual conference today in Washington, DC.

The recipients of this year's prestigious honor are Mark Atkinson, Ph.D., director of the JDRF Gene Therapy Center for Diabetes and Diabetic Complications at the University of Florida and University of Miami; Michael Haller, M.D., a professor of pediatrics and a researcher at the University of Florida; and Desmond Schatz, M.D., medical director of the Diabetes Center of Excellence and associate director of the General Clinical Research Center at the University of Florida.

The three researchers are involved in several innovative JDRF-funded studies to accelerate the development of a cure for type I diabetes, including using umbilical cord blood stem cells as a potential therapy and investigating drug treatments used in tandem to provide immune suppression while boosting the regeneration of insulin-producing cells.

"We are honored to present JDRF's 2008 Excellence in Clinical Research Award to Drs Schatz, Haller and Atkinson. Their willingness to challenge conventional wisdom and consequent ground-breaking work in translating novel scientific insights into new, potentially life-changing therapies and cures represents the sort of leadership we value most. Their pioneering research in the area of preservation and restoration of pancreatic beta cell mass and function in type 1 diabetes has moved us many steps closer to a cure," stated Mary Tyler Moore and S. Robert Levine MD.

Dr. Atkinson has spent 25 years in the field of type 1 diabetes research. An internationally-recognized authority in several research fields and a past JDRF chair for medical science research, his work focuses on disease prediction and prevention, environmental factors in the onset of the disease and the study of gene therapy to cure diabetes and prevent its complications.

Dr. Haller has committed his career to developing safe and effective therapies to prevent and reverse type 1 diabetes. The recipient of several prestigious awards for his work, he is an active investigator in TrialNet Research funded by the National Institute of Health and chairs the Clinical Implementation Committee of the TEDDY study, which focuses on determining the role of environmental factors in the development of diabetes.

Dr. Schatz has been involved in type 1 diabetes research since the 1980s, focusing on prediction, natural history, genetics and prevention of the disease, as well as the management of children and adolescents with type 1 diabetes. The author of more than 170 manuscripts, he is the principal investigator on several JDRF and NIH projects and co-principal investigator on a JDRF-funded project studying the origin and development of type 1 diabetes.

The annual "Excellence in Clinical Research Award" recognizes outstanding scientists who are pursuing research toward finding a cure for type 1 diabetes and its complications. Presented each year at JDRF's conference, it is named for Moore and Levine in honor of their longtime extraordinary efforts and commitment to JDRF's mission to find a cure for diabetes and its complications through the support of research.


'/>"/>

Contact: Jillian Lubarsky
jlubarsky@jdrf.org
212-479-7626
Juvenile Diabetes Research Foundation International
Source:Eurekalert

Related biology news :

1. Palm Beach County wants to establish a Max Planck Institute in Florida
2. New south Florida nursery to focus on staghorn corals
3. ASNTR 15th anniversary meeting to be held May 1-3 in Florida
4. DHS Expands Biometrics-at-Sea Program to the Florida Straits
5. Fecal microorganisms inhabit sandy beaches of Florida
6. Researchers identify proteins involved in new neurodegenerative syndrome
7. Texas researchers and educators head for Antarctica
8. MGH researchers describe new way to identify, evolve novel enzymes
9. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
10. U of MN researchers discover noninvasive diagnostic tool for brain diseases
11. U of Minnesota researchers discover noninvasive diagnostic tool for brain diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
Breaking Biology Technology: